Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now?

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best cheap biotech stocks to buy now. Jazz Pharmaceuticals (NASDAQ:JAZZ) was initiated with an Overweight rating by Barclays on February 27, with the firm setting a $224 price target on the shares and stating that its key opinion leader calls show that the company’s central nervous system base business is “sticky.” It also sees “oncology-fueled” Ziihera growth in multiple tumor types in the longer term, with significant readouts in 2027 for the company.

Jazz Pharmaceuticals (NASDAQ:JAZZ) received several other bullish rating updates on February 25. Morgan Stanley lifted the price target on the stock to $226 from $225 and maintained an Overweight rating on the shares, updating estimates on the stock following the release of its fiscal Q4 report. The same day, Deutsche Bank also lifted the price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $255 from $210 and reiterated a Buy rating on the shares.

Jazz Pharmaceuticals (NASDAQ:JAZZ) also received a bullish rating update from BofA on February 25. The firm reiterated a Buy rating on the shares and raised the price target to $275 from $263, telling investors that while the fiscal Q4 results included modest top and bottom-line beats, FY26 revenue guidance was about in-line with the firm’s forecast and 3% below consensus at the mid-point. The firm further noted that “solid” guidance should allow investors to own the stock for Ziihera’s gastroesophageal adenocarcinoma launch.

Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection. These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.